Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-07-12
2005-07-12
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S329000, C544S295000, C544S296000, C544S122000, C540S575000, C540S601000, C514S256000, C514S252200, C514S252180, C514S252110, C514S235800
Reexamination Certificate
active
06916804
ABSTRACT:
The subject invention provides compounds having the structure:wherein R1is substituted or unsubstituted phenyl or a 5-6 membered heterocyclic or heteroaromatic ring containing from 1 to 5 heteroatoms; R2is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety; R3is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R2and R3are joined to form a heterocyclic ring; wherein the dashed line represents a second bond which may be present or absent, and when present R3is oxygen; R4and R5are each independently substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R4NR5together form a substituted or unsubstituted monocyclic or bicyclic, heterocyclic or heteroaryl moiety containing from 1 to 6 heteroatoms; R12is hydrogen, alkyl, halogen or cyano; and n is 0, 1, 2, 3 or 4, or an enantiomer, or a specific tautomer, or a pharmaceutically acceptable salt thereof and a method for treating a disease associated with the A2badenosine receptor by administering a therapeutically effective amount of the compounds of the invention.
REFERENCES:
patent: 5516894 (1996-05-01), Reppert
patent: 5780450 (1998-07-01), Shade
patent: 5889026 (1999-03-01), Alanine et al.
patent: 6117878 (2000-09-01), Linden
patent: 6465456 (2002-10-01), Springer et al.
patent: WO9747601 (1997-12-01), None
patent: WO9942093 (1999-08-01), None
patent: WO9962518 (1999-12-01), None
patent: WO9964407 (1999-12-01), None
patent: WO0139777 (2001-06-01), None
patent: WO0257267 (2002-07-01), None
Baraldi et al. Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes, Curr. Pharm. Design 8: 2299-2332 ,2002.
Gao, Z. et al., “A28Adenosine and P2Y2Receptors Stimulate Mitogen-activated Protein Kinase in Human Embryonic Kidney-293 Cells”J. Bio. Chem.(1999) 274(9): 5972-5980 (Exhibit 20).
Grant, M.B. et al., “Proliferation, Migration, and ERK Activation in Human Retinal Endothelial Cells through A2BAdenosine Receptor Stimulation”Invest. Opthalmol. Vis. Sci.(2001) 42(9): 2068-2073 (Exhibit 21).
Haynes, J. Jr. et al., “5-(N-ethylcarboxamido)adenosine desensitizes the A2b-adenosine receptor in lung circulation”Am. J. Physiol.(1999) 276(6):H1877-H1883 (Exhibit 22).
Linden, J. et al., “The Structure and Function of A1and A2BAdenosine Receptors”Life Sciences(1998) 62(17-18): 1519-1524 (Exhibit 23).
Mirabet, M. et al., “Expression of A2Badenosine receptors in human lymphocytes: their role in T cell activation”J. Cell. Sci.(1999) 112(4): 491-502 (Exhibit 24).
Muller, C.E. and Stein, B., “Adenosine Receptor Antagonists: Structures and Potential Therapeutic Applications”Current Pharm. Design(1996) 2:501-530 (Exhibit 25).
Muller, C.E., “A1Adenosine receptor antagonists”Exp. Opin. Ther. Patents(1997) 7(5):419-440 (Exhibit 26).
Nyce, J.W. and Metzger, J.W., “DNA antisense therapy for asthma in an animal model”Nature(1997) 385: 721-725 (Exhibit 27).
Ralevic, V. and Burnstock, G., “Receptors for Purines and Pyrimidines”Pharmacol. Rev.(1998) 50(3): 413-492 (Exhibit 28).
Regnauld, K. et al. “G-protein αolf subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells”Oncogene(2002) 21(25): 4020-4031 (Exhibit 29).
Strohmeier, G.R. et al., “The A2bAdenosine Receptor Mediates cAMP Responses to Adenosine Receptor Agonists in Human Intestinal Epithelia”J. Bio. Chem.(1995) 270: 2387-2394 (Exhibit 30).
Williams, E.F. et al., “Nucleoside transport sites in a cultured human retinal cell line established by SV-40 T antigen gene”Current Eye Research(1994) 13: 109-118 (Exhibit 31).
Woods, C.L., and Blazynski, C., “Characterization of Adenosine A1-receptor Binding Sites in Bovine Retinal Membranes”Exp. Eye Research(1991) 53: 325-331 (Exhibit 32); and.
Van Niel, M.B. et al., “Fluorination of 3-(3-(Piperidin-1-yl)propyl)indoles and 3-(3-(Piperazin-1-yl)propyl)indoles Gives Selective Human 5-HT1DReceptor Ligands with Improved Pharmacokinetic Profiles”J. Med. Chem.(1999) 42(12): 2087-2104 (Exhibit 33).
Blazynski, C., “Discrete Distributions of Adenosine Receptors in Mammalian Retina”J. Neurochem.(1990) 54(2): 648-655 (Exhibit 11).
Braas, K.M. et al., “Endogenous adenosine and adenosine receptors localized to ganglion cells of the retina”Proc. Natnl. Acad. Sci.(1987) 84: 3906-3910 (Exhibit 12).
Christofi, F.L. et al., “Differential Gene Expression of Adenosine A1, A2a, A2b, and A3 Receptors in the Human Enteric Nervous System”J. Comp. Neurol.(2001) 439(1): 46-64 (Exhibit 13).
Corset, V. et al., “Netrin-1-mediated axon outgrowth and cAMP production requires interaction with adenosine A2b receptor”Nature(2000) 407(6805): 747-750 (Exhibit 14).
Dubey, R.K. et al., “A2BReceptors Mediate the Antimitogenic Effects of Adenosine in Cardiac Fibroblasts”Hypertension(2001) 37: 716-721 (Exhibit 15).
Faivre, K. et al., “Suppression of Cellular Invasion by Activated G-Protein Subunits Gαo, Gαil, and Gαi3 and Sequestration of Gβγ”Mol. Pharmacol.(2001) 60: 363-372 (Exhibit 16).
Feoktistov, I. and Biaggioni, I., “Adenosine A2bReceptors”Pharmacol. Rev.(1997) 49(4): 381-402 (Exhibit 17).
Feoktistov, I. et al., “Differential Expression of Adenosine Receptors in Human Endothelial Cells”Circulation Research(2002) 90: 531-538 (Exhibit 18).
Feoktistov, I., et al., “Adenosine A2Breceptors: a novel therapeutic target in asthma?” (1998)TiPS19: 148-153 (Exhibit 19).
Castelhano Arlindo
Collington Eric
McKibben Bryan
Steinig Arno
Cooper & Dunham LLP
Liu Hong
OSI Pharmaceuticals, Inc.
Raymond Richard L.
White John P.
LandOfFree
Pyrimidine A2b selective antagonist compounds, their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidine A2b selective antagonist compounds, their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine A2b selective antagonist compounds, their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3390598